menu
    • menu

    Company profile for BioSyngen

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Biosyngen Pte. Ltd. is the Global Leader in Cell and Gene Therapy and was established in Singapore on 1 July 2016 as an immuno-oncology company. It collaborates with leading biomedical research and clinical institutes in Germany, Australia, China, and Singapore. BioSyngen is utilizing our proprietary technology platforms to develop next-generation CAR-T and TCR-T therapies to target unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioSyngenSingapore Flag
    Country
    Country
    Singapore
    Address
    Address
    Taiseng Exchange, 5 Tai Seng Avenue, #08-51/52/53/54 , Tower C
    Telephone
    Telephone
    +65 69080398
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biosyngen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biosyngen/?originalSubdomain=sg
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte
    Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte

    20 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biosyngen-best-in-class-next-generation-tumor-infiltrating-lymphocyte-til-technology-debuts-on-esmo-2024-annual-meeting-302254058.html

    PR NEWSWIRE
    20 Sep 2024
    Share Share
    Biosyngen Presents SUPER-T Technology At ESMO 2024
    Biosyngen Presents SUPER-T Technology At ESMO 2024

    19 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biosyngen-presents-pioneeringconditional-activation--armor-enhancement-super-t-technology-at-esmo-2024-302253153.html

    PR NEWSWIRE
    19 Sep 2024
    Share Share
    Biosyngen's CAR-T Asset for Solid Tumors Enters Phase II, Data Debut at ESMO
    Biosyngen's CAR-T Asset for Solid Tumors Enters Phase II, Data Debut at ESMO

    18 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biosyngens-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii-trial-phase-i-trial-data-debut-at-esmo-2024-annual-congress-302251709.html

    PR NEWSWIRE
    18 Sep 2024
    Share Share
    Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial
    Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial

    12 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biosyngens-brg01-receives-fda-approval-for-phase-ii-clinical-trial-302220007.html

    PR NEWSWIRE
    12 Aug 2024
    Share Share
    Biosyngen partners with Singapore's A*STAR to advance autoimmune therapy
    Biosyngen partners with Singapore's A*STAR to advance autoimmune therapy

    02 Aug 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/26/24679/biosyngen-partners-with-singapores-astar-to-advance-autoimmune-therapy-.html

    BIOSPECTRUM ASIA
    02 Aug 2024
    Share Share
    Biosyngen's BRG01 Enters Phase II For EBV-Specific CAR-T Therapy
    Biosyngen's BRG01 Enters Phase II For EBV-Specific CAR-T Therapy

    16 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biosyngens-brg01-enters-phase-ii-clinical-trial-a-first-in-kind-autologous-ebv-specific-car-t-therapy-for-solid-tumors-on-recurrentmetastatic-nasopharyngeal-carcinoma-302197874.html

    PR NEWSWIRE
    16 Jul 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search